At a three-day event, hepatology experts focused on improving patient outcomes, particularly in ICU care, while exploring ...

The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is ...

A UK clinical trial is testing whether the dietary supplement HMB can improve strength and quality of life for cirrhosis ...

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis patients ... 3 SYNCHRONY Real-World study ...

The researcher, a global liver damage expert, sounds the alarm over our limited awareness of the connection between drug ...

and establish whether HMB can indeed deliver real benefits for people with cirrhosis and those around them.” Those leading the project also held meetings with patients diagnosed with liver ...

Akero's 50mg EFX led to a 24% effect size for cirrhosis reversal ... including real-time stock ratings, insider trades, and government trading signals. Among patients with baseline and week ...

Yale said 87% of patients for whom liver biopsies were collected ... EFX in patients with compensated cirrhosis due to MASH. The third clinical trial is a real-world study in patients with either ...

Are you drinking more than you should? Not in a way that's destroying your relationships or career - or that involves ...

Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional safety and efficacy in a Phase 2b study. A 50-milligram dose of efruxifermin ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b also ...